Approximately 8.25 million sales revenue for temcell in fy 2016- not a bad for the start. Waiting for FY 2017 sales figures. I don’t have any concern for the agvhd success . However, i’m bit cautious about the credit sussie analysts comments about possibilities of MSB requiring more data set for back pain and heart failure for approval. Is this assertion true? My thinking is 21st century cure act would enable mesoblast to file for approval if existing phase 3 trial is successful and if necessary MSB might require to submit post product launch data. Guys, what are your take on this?
Approximately 8.25 million sales revenue for temcell in fy 2016-...
Add to My Watchlist
What is My Watchlist?
